Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Carmat    ALCAR   FR0010907956

CARMAT

(ALCAR)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
08/12/2019 08/13/2019 08/14/2019 08/15/2019 08/16/2019 Date
19.98(c) 20.1(c) 19.96(c) 19.8(c) 19.5(c) Last
1 992 825 811 2 426 1 817 Volume
-0.35% +0.60% -0.70% -0.80% -1.52% Change
More quotes
Financials (EUR)
Sales 2019 -
EBIT 2019 -42,8 M
Net income 2019 -42,4 M
Finance 2019 0,63 M
Yield 2019 -
Sales 2020 -
EBIT 2020 -43,1 M
Net income 2020 -42,4 M
Debt 2020 46,9 M
Yield 2020 -
P/E ratio 2019 -3,87x
P/E ratio 2020 -3,54x
EV / Sales2019 infx
EV / Sales2020 infx
Capitalization 183 M
More Financials
Company
Carmat specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all... 
More about the company
Latest news on CARMAT
07/04CARMAT : has Presented Additional Interim Results of the PIVOTAL Study at the AS..
BU
05/21CARMAT : Announces the Resumption of Production of Prostheses for the PIVOTAL St..
BU
04/12CARMAT : Announces a Delay in the Resumption of Production of Prostheses for the..
AQ
04/10CARMAT : Announces a Delay in the Resumption of Production of Prostheses for the..
BU
03/29CARMAT : the Shareholders' Meeting approves all of the resolutions supported by ..
BU
03/28CARMAT : to Present the Positive Interim Results of the First Part of the PIVOTA..
BU
02/13CARMAT : Reports Its 2018 Annual Results and Confirms Its 2019 Development Prosp..
BU
01/21CARMAT : 2019 Financial Calendar
BU
01/16CARMAT : presents positive interim results of the first part of its PIVOTAL stud..
AQ
01/15CARMAT : presents positive interim results of the first part of its PIVOTAL stud..
BU
More news
Analyst Recommendations on CARMAT
More recommendations
Sector news : Medical Devices & Implants
08/16MEDTRONIC : Says FDA Approves Evolut TAVR System for Expanded Indication
DJ
08/16ZIMMER BIOMET : Gets FDA Approval for Scoliosis Treatment
DJ
08/16MEDTRONIC : Approved To Proceed With Pivotal Trial for Extended Wear Infusion Se..
DJ
08/12TSO3 : to Be Acquired by Stryker Corp. in $51.7 Million Deal
DJ
08/07EssilorLuxottica Eyes More Acquisitions -Bloomberg
DJ
More sector news : Medical Devices & Implants
Chart CARMAT
Duration : Period :
Carmat Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARMAT
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 25,15  €
Last Close Price 19,50  €
Spread / Highest target 29,7%
Spread / Average Target 29,0%
Spread / Lowest Target 28,2%
EPS Revisions
Managers
NameTitle
Stéphane Piat Chief Executive Officer & Director
Jean-Pierre Garnier Chairman
Pascale d’Arbonneau Chief Financial & Administrative Officer
Marc Grimmé Director-Research & Development
Piet Jansen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CARMAT-17.02%207
STRYKER CORPORATION38.44%80 330
SMITH & NEPHEW29.61%19 879
GLAUKOS CORP12.05%2 236
INSPIRE MEDICAL SYSTEMS INC54.98%1 558
JAPAN LIFELINE CO., LTD.28.74%1 307